MISSION: Address the Growing Unmet Need
Associated with Substance Use Disorder
By Discovering, Developing and Commercializing
Safe and Effective Pharmacotherapies
to Treat and Prevent Addiction
Peter Strumph, Chief Executive Officer and Founder
- Former SVP Operations, Portola Pharmaceuticals; CEO, Codexis; CEO, Nile Therapeutics; SVP Operations, CVT; Operations Planning, Biogen; Lieutenant, US Navy
Ivan Diamond, MD, PhD, Chief Scientific Officer and Founder
- Former Senior Advisor, Gilead Sciences; VP Neurology Research, CVT; Vice Chair, UCSF Department of Neurology; Founding Director, UCSF Ernest Gallo Clinic and Research Center
NIH/IHV PRESS RELEASE: Sept 19, 2018
In addition to Lou Lange, Ivan Diamond, and Peter Strumph, the BOD includes:
William Lee, PhD, Executive Vice President Research, Gilead Sciences
Howard Jaffe, MD, President and COB of the Gilead Foundation. Former CMO Gilead Sciences
NIH PRESS RELEASE: March 21, 2019
News
The Amygdala founders have deep and varied expertise in drug development and the addiction space. In addition to our individual experiences, we are all former members of the executive management team that built CV Therapeutics into a FIPCO and developed two first-in-class NCEs approved in the US and EU and achieved guideline status in both territories with current global revenues over $1.6B.
The Board of Directors
Mack Mitchell, MD, Chief Medical Officer
- EVP of Health System at the University of Texas Southwestern Medical Center; former Chief of Gastroenterology and the Medical Director of Ambulatory Services at Johns Hopkins Bayview Medical Center
The Team
Adrienne MacMillan, Chief Financial Officer and Founder
- Former CFO, Rapidscan Pharma Solutions; VP Finance, CVT
Brent Blackburn, PhD, Chief Development Officer and Founder
- Former CEO, Rapidscan Pharma; SVP R&D, CVT
AMYGDALA PRESS RELEASE: October 21, 2019
Amygdala Neurosciences Awarded $1.35 million NIH Grant to Conduct Long Term, Phase 3 Enabling, Toxicology Studies
AMYGDALA PRESS RELEASE: Sept 12, 2018
Lou Lange, MD, PhD, Executive Chairman and Founder
- General Partner Asset Management; Senior Advisor to CEO, Gilead Sciences
- Former Founder Chairman & CEO, CV Therapeutics; Chief of Cardiology and Professor of Medicine at Jewish Hospital Washington University
AMYGDALA PRESS RELEASE: November 18, 2019
Amygdala Neurosciences Announces $5.6M Financing and Dr. Mack Mitchell's Expanded Role as CMO
ANS-6637 is in Phase 2 Clinical Development to Treat Substance Use Disorders
ANS-6637 is a new chemical entity selective and reversible ALDH2 inhibitor. Based on its mechanism of action in the brain to prevent pathophysiologic dopamine surge without changes to basal dopamine (Nature Medicine 16:1024, 2010), ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse. In preclinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anti-anxiety properties in models of stress.
Amygdala acquired the asset ANS-6637 as a spin out from Gilead Sciences. ANS-6637 has completed extensive Phase 1 studies in 150 human subjects. ANS-6637 is currently in Phase 2 clinical development for alcohol use disorder with plans to start additional Phase 2 studies in opioid use disorder and smoking cessation.
Contact: mailroom@amygns.com
Amygdala Neurosciences, Inc. © COPYRIGHT